Key Highlights
- UNH shares advanced 8.16% during the past five trading sessions, featuring a significant single-day surge
- CMS approved a 2.48% Medicare Advantage reimbursement rate increase for 2027
- Bernstein analysts lifted their price target to $411 while maintaining a Buy recommendation
- HSBC moved UNH to Hold from Sell; Baird’s Michael Ha maintains the sole Underperform stance
- The stock remains approximately 7% lower year to date and over 50% beneath its 2024 high
UnitedHealth Group (UNH) experienced its strongest weekly performance in seven months, advancing more than 8% following favorable Medicare Advantage payment rates from federal regulators.
UnitedHealth Group Incorporated, UNH
The Centers for Medicare & Medicaid Services confirmed a 2.48% increase in 2027 Medicare Advantage reimbursement rates. This represented a substantial improvement compared to an initial proposal that suggested rates would remain essentially unchanged.
The regulatory decision triggered a substantial single-session rally. Market participants had anticipated less favorable terms, making the enhanced rate a welcome development.
Medicare Advantage has served as a primary growth driver for UNH throughout the past decade. However, escalating medical expenses combined with constrained government reimbursements had begun compressing profit margins, making this outcome particularly significant.
Bernstein analysts responded immediately following the announcement. The firm elevated its price objective on UNH to $411 while reaffirming its Buy recommendation.
Analyst commentary from Bernstein indicated the CMS ruling transforms what might have been approximately 4% negative impact on 2027 earnings into projected earnings expansion of roughly 1.4%. This represents a substantial shift in the financial outlook.
HSBC analyst Sidharth Sahoo elevated UNH to Hold on the same day. The upgrade reflected a recalibration of the risk assessment rather than outright bullishness.
Dissenting Perspective
Some analysts remain cautious despite the positive development. Baird’s Michael Ha maintained his Underperform rating, representing the sole sell-equivalent view among the 31 analysts tracking the stock.
Ha’s thesis centers on the possibility that the payment increase may provide only temporary relief. He highlighted that fundamental challenges facing value-based care models persist.
This perspective deserves consideration. The Medicare Advantage segment continues facing a complex operating environment, despite the improved reimbursement rate.
Broader Context
UNH recently forecast declining 2026 revenue — potentially marking its first annual revenue decrease in more than three decades. Membership is projected to decline across commercial, Medicare, and Medicaid segments.
The stock remains approximately 7% lower year to date while trading more than 50% beneath its 2024 peak. This week’s rally reduces those losses, though a substantial valuation gap persists.
Wall Street sentiment remains generally favorable. Among 31 analysts covering UNH, 22 maintain Buy ratings. The consensus 12-month price target implies approximately 17% potential upside from current trading levels.
Optum, UNH’s health services division encompassing pharmacy benefits and care delivery, continues delivering earnings stability while the core insurance operations face challenges.
Investors are focused on Q1 2026 earnings results. Medical cost trends along with updated Medicare Advantage profitability guidance will be critical focus areas.
